Raymond Vanholder, MD, PhDA
Dr. Vanholder has published almost 700 papers, including reviews and book chapters, on adequacy of dialysis, uremic toxicity and various topics related to clinical nephrology. He serves as a member of the editorial review board of several journals and is subject editor of Nephrology Dialysis and Transplantation. Up till autumn 2010, he has been chairman of the European Uremic Toxin Work Group (EUTox) and member of the Executive Board and treasurer of Kidney Disease Improving Global Outcomes (KDIGO). Up till summer 2011 he was member of the Scientific Advisory Board (SAB) of the European Renal Association – European Dialysis and Transplantation Association (ERA-EDTA) and chairman of the European Renal Best Practice (ERBP), the guidance body of ERA-EDTA. Before that, he coordinated the European Best Practice Guidelines (EBPG) on hemodialysis.
He chairs the Renal Disaster Relief Task Force (RDRTF) of the International Society of Nephrology (ISN) and in this function participated as member or coordinator in several international relief operations. Dr.Vanholder was founding president of the Belgian Society of Nephrology (BVN-SBN), is past president of the European Society of Artificial Organs (ESAO) and current president of ERA-EDTA.
PUBLICATIONS and PRESENTATIONS:
A. INTERNATIONAL JOURNALS ( A publications ): 607
B. BELGIAN JOURNALS: 45
C. PROCEEDINGS: 40
D. ABSTRACTS & LETTERS TO THE EDITOR: 482
E. CHAPTERS IN BOOKS: 40
F. PRESENTATIONS: 1598
G. THESES: 76
MOST IMPORTANT CONTRIBUTIONS TO THE LITERATURE:
15 most cited publications
1) Kidney Int, 63, 1934, 2003-355;
2) Lancet, 365, 417, 2005 – 304;
3) J Am Soc Nephrol, 11, 1553, 2000-208;
4) Nephrol Dial Transplant, 20, 1048, 2005 – 194;
5) J Am Soc Nephrol, 10, 846, 1999-191;
6) Kidney Int, 39, 320, 1991-176;
7) Kidney Int, 42,426, 1992 -151;
8) J Am Soc Nephrol, 14, 1022, 2003 – 146;
9) Am J Med, 110, 438, 2001-130;
10) J Am Soc Nephrol, 3, 1541, 1993-126;
11) IJAO, 24, 695, 2001-120;
12) JASN, 11, 116, 2000-116;
13) KI, 66, 1310, 2004-112;
14) JASN, 10, 1815, 1999-107;
15) NDT, 22 (Suppl. 2), 88-105.
15 highest ranked publications
1) N Engl J Med, 354,1052, 2006-53.3;
2) Lancet, 354,1316, 1999-38.3;
3) Lancet, 365, 417, 2005-38.3;
4) Lancet, 372, 1863, 2008-38.3;
5) JAMA, 288, 2599, 2002-30.0;
6) Nat Med, 11, 223, 2005-22.5;
7) Circulation , 112, 2875, 2005-17.7;
8) Brit Med J, 1, 1138, 1977-14.1;
9) J Clin Invest, 96, 50,1995-13.1;
10) Eur Heart J, 28, 478, 2007-10.1;
11) JASN, 15, 1071, 2004-9.7;
12) JASN, 17, 923, 2006-9.7;
13) JASN, 19, 863, 2008-9.7;
14) JASN, 19, 1253, 2008-9.7;
15) JASN, 19, 645, 2009-9.7;
(Next to these five, 23 more publications in JASN).
Status 01/07/2012:
Number of A papers: 576
Number of citations: 10527
Total impact factor: 2240
Publications with impact factor > 5: 151
Hirsch Index: 53
MAIN INTERESTS:
identification, analysis and kinetic studies of uremic retention solutes, biochemistry of uremia, acute renal failure especially in disasters.